GLP-1 and Blood Pressure: Does Ozempic Lower BP? (The Data)

High blood pressure (hypertension) affects nearly half of American adults and is a leading risk factor for heart attack and stroke. If you’re considering Ozempic or semaglutide, one question worth answering upfront: does it actually help with blood pressure? The short answer is yes — here’s what the data shows and how it works.

What the Clinical Trials Show

Multiple large-scale semaglutide trials have measured blood pressure as a secondary endpoint, and the results are consistently positive.

In the SUSTAIN trials (type 2 diabetes population), semaglutide reduced systolic blood pressure by an average of 3–6 mmHg compared to placebo. Diastolic blood pressure dropped by around 1–2 mmHg. These are modest reductions compared to dedicated antihypertensive medications, but they’re clinically meaningful and come without additional medication burden.

In the STEP trials (non-diabetic obesity population), similar results emerged — systolic BP reductions of around 4–6 mmHg over 68 weeks. Importantly, these occurred even after controlling for the weight loss effect, suggesting semaglutide has direct cardiovascular benefits beyond just shrinking adipose tissue.

The SELECT trial — which studied semaglutide specifically in overweight/obese patients with cardiovascular disease but without diabetes — showed significant reductions in major cardiovascular events, with blood pressure improvement as a likely contributing mechanism.

How Does Semaglutide Lower Blood Pressure?

The blood pressure reduction from semaglutide comes through multiple pathways:

Weight loss effect: The most obvious mechanism. Losing 10–15% of body weight reduces the workload on the cardiovascular system, reduces arterial stiffness, and lowers circulating blood volume. For every 5 kg of weight lost, systolic BP typically drops by around 2–3 mmHg.

Direct GLP-1 receptor effects: GLP-1 receptors exist in blood vessel walls and the heart. Semaglutide appears to have direct vasodilatory effects — relaxing blood vessel walls — independent of weight loss. This explains why BP reductions in some trials exceed what weight loss alone would predict.

Sodium excretion: GLP-1 agonists increase sodium excretion through the kidneys, which reduces fluid retention and lowers blood pressure — a mechanism similar to how some diuretics work.

Reduced sympathetic nervous system activity: Some research suggests GLP-1 agonists may reduce the overactivation of the sympathetic (“fight or flight”) nervous system that contributes to hypertension in people with obesity.

How Much Blood Pressure Reduction Can You Expect?

Combining the weight loss and direct effects, a realistic expectation for someone starting semaglutide who has hypertension and is significantly overweight:

• From weight loss alone (assuming 10–15% body weight loss): approximately 5–10 mmHg systolic reduction
• From direct GLP-1 effects: approximately 3–6 mmHg additional
• Total realistic range: 8–16 mmHg systolic reduction

For context: a 10 mmHg reduction in systolic blood pressure is associated with a roughly 20–25% reduction in major cardiovascular events in population studies. It’s not trivial.

Does This Mean You Can Stop Your Blood Pressure Medication?

Not without talking to your doctor first. As your blood pressure comes down on semaglutide, your physician may recommend reducing or stopping antihypertensive medications to avoid your blood pressure dropping too low. This needs to be done with monitoring, not independently.

Some patients on semaglutide do successfully reduce or eliminate blood pressure medications under physician supervision — particularly those whose hypertension was primarily driven by excess body weight. This is one of the real-world benefits beyond just weight loss that makes GLP-1 therapy compelling from a holistic health perspective.

Heart Rate: The One Caution

While semaglutide lowers blood pressure, it typically raises resting heart rate slightly — by around 1–4 beats per minute on average. For most people, this is clinically insignificant. However, people with pre-existing tachycardia (abnormally fast heart rate) or cardiac arrhythmias should discuss this with their cardiologist before starting semaglutide.

The clinical consensus is that the cardiovascular benefits (reduced blood pressure, reduced MACE events, weight loss) far outweigh the minor heart rate increase for most patients. But it’s worth flagging to your prescriber.

Semaglutide and Cardiovascular Disease

The blood pressure story connects to a bigger cardiovascular narrative. SUSTAIN 6 showed a 26% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in high-risk T2D patients. SELECT showed similar protection in overweight/obese non-diabetic patients with established cardiovascular disease.

Blood pressure reduction is one piece of this — alongside weight loss, improved lipid profiles, reduced inflammation, and direct cardioprotective effects. Semaglutide is now recommended by cardiological guidelines for patients with T2D and high cardiovascular risk, and guidelines are expanding to cover the non-diabetic obesity population.

Frequently Asked Questions

Affiliate disclosure: This article contains sponsored links. We may earn a commission if you click through and make a purchase. See our full disclosure.